Targeting HER2-positive cancer cells with receptor-redirected anthrax protective antigen

Molecular Oncology

Volumn 7, Issue 3, 2013, Pages 440-451

  McCluskey, Andrew J ^a   Olive, Andrew J ^a   Starnbach, Michael N ^a   Collier, R John ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Affibody; Anthrax toxin; Binary toxin; HER2 neu; Immunotoxin

Indexed keywords

ANTHRAX PROTECTIVE ANTIGEN; ANTHRAX TOXIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYBRID PROTEIN; PROTEIN VARIANT; RECOMBINANT PROTEIN; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER RESISTANCE; CELL VIABILITY; DRUG CYTOTOXICITY; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; WILD TYPE;

EID: 84878116059     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.12.003     Document Type: Article

References (43)

1. Abi-Habib R.J., et al. A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types. Molecular Cancer Therapeutics 2006, 5(10):2556-2562.
2. Arteaga C.L., et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nature Reviews Clinical Oncology 2012, 9(1):16-32.
3. Berchuck A., et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Research 1990, 50(13):4087-4091.
4. Bradley K.A., et al. Identification of the cellular receptor for anthrax toxin. Nature 2001, 414(6860):225-229.
5. Carter P.J., Senter P.D. Antibody-drug conjugates for cancer therapy. Cancer Journal (Sudbury, Mass.) 2008, 14(3):154-169.
6. Collier R.J., Cole H.A. Diphtheria toxin subunit active in vitro. Science 1969, 164(884):1179-1181.
7. Collier R.J. Effect of diphtheria toxin on protein synthesis: inactivation of one of the transfer factors. Journal of Molecular Biology 1967, 25(1):83-98.
8. Collier R.J. Membrane translocation by anthrax toxin. Molecular Aspects of Medicine 2009, 30(6):413-422.
9. Cunningham K., et al. Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(10):7049-7053.
10. Duesbery N.S., et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998, 280(5364):734-737.
11. Duesbery N.S., et al. Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(7):4089-4094.
12. Endo Y., Tsurugi K. RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes. The Journal of Biological Chemistry 1987, 262(17):8128-8130.
13. Foss F.M. DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clinical Lymphoma 2000, 1(Suppl. 1):S27-S31.
14. Gravalos C., Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2008, 19(9):1523-1529.
15. Honjo T., Nishizuka Y., Hayaishi O. Diphtheria toxin-dependent adenosine diphosphate ribosylation of aminoacyl transferase II and inhibition of protein synthesis. The Journal of Biological Chemistry 1968, 243(12):3553-3555.
16. Kintzer A.F., et al. The protective antigen component of anthrax toxin forms functional octameric complexes. Journal of Molecular Biology 2009, 392(3):614-629.
17. Klimpel K.R., et al. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proceedings of the National Academy of Sciences of the United States of America 1992, 89(21):10277-10281.
18. Köninki K., et al. Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Letters 2010, 294(2):211-219.
19. Koo H.-M., et al. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(5):3052-3057.
20. Lacy D.B., et al. Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(36):13147-13151.
21. Leppla S.H. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proceedings of the National Academy of Sciences of the United States of America 1982, 79(10):3162-3166.
22. Lewis Phillips G.D., et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Research 2008, 68(22):9280-9290.
23. Liu S., et al. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Research 2000, 60(21):6061-6067.
24. Löfblom J., et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Letters 2010, 584(12):2670-2680.
25. Madhumathi J., Verma R.S. Therapeutic targets and recent advances in protein immunotoxins. Current Opinion in Microbiology 2012.
26. Mechaly A., McCluskey A.J., Collier R.J. Changing the receptor specificity of anthrax toxin. mBio 2012, 3(3). pp. e00088-12, Available at:. http://mbio.asm.org/content/3/3/e00088-12.
27. Miller C.J., Elliott J.L., Collier R.J. Anthrax protective antigen: prepore-to-pore conversion. Biochemistry 1999, 38(32):10432-10441.
28. Milne J.C., et al. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. The Journal of Biological Chemistry 1994, 269(32):20607-20612.
29. Mogridge J., et al. The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(10):7045-7048.
30. Nagy P., et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Research 2005, 65(2):473-482.
31. Nord K., et al. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nature Biotechnology 1997, 15(8):772-777.
32. Orlova A., et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Research 2006, 66(8):4339-4348.
33. Pastan I., et al. Immunotoxin treatment of cancer. Annual Review of Medicine 2007, 58:221-237.
34. Rainey G.J.A., et al. Receptor-specific requirements for anthrax toxin delivery into cells. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(37):13278-13283.
35. Rogers M.S., et al. Mutant anthrax toxin B moiety (protective antigen) inhibits angiogenesis and tumor growth. Cancer Research 2007, 67(20):9980-9985.
36. Scobie H.M. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proceedings of the National Academy of Sciences 2003, 100(9):5170-5174.
37. Slamon D.J., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244(4905):707-712.
38. Tanner M., et al. Characterization of a novel cell line established from a patient with herceptin-resistant breast cancer. Molecular Cancer Therapeutics 2004, 3(12):1585-1592.
39. Vitale G., et al. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochemical and Biophysical Research Communications 1998, 248(3):706-711.
40. Vogel C.L., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2002, 20(3):719-726.
41. Wikman M., et al. Selection and characterization of HER2/neu-binding affibody ligands. Protein Engineering, Design & Selection: PEDS 2004, 17(5):455-462.
42. Williams D.P., et al. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Engineering 1987, 1(6):493-498.
43. Young J.A.T., Collier R.J. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annual Review of Biochemistry 2007, 76(1):243-265.